ArticleThe Pediatric infectious disease journal2026
A Prospective Cohort Study of Hepatitis B Virus Vaccination in Pediatric Heart Transplant Recipients: Cellular and Humoral Immune Responses and the Role of Innate Immunity.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Detection of latent tuberculosis infection in patients prior to and following heart transplantation.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVaccination is a key strategy to reduce infectious disease mortality. In pediatric heart transplant recipients (HTRs), the use of immunosuppressive therapy weakens immune responses, increasing the risk of viral infections. This study aimed to evaluate the immunogenicity of hepatitis B virus (HBV) revaccination in this vulnerable population.
methodsA prospective longitudinal study was conducted in HTRs under 18 years of age who received HBV revaccination. Blood samples were collected at study inclusion (baseline) and after the final vaccine dose post-solid organ transplant (SOT; follow-up). Seroprotection was measured by quantifying plasma antibodies to hepatitis B surface antigen (anti-HBs) IgG. Cellular responses were assessed by flow cytometry, evaluating HBV-specific T-cell and natural killer (NK) cell activity following in vitro stimulation with HBV peptides.
resultsTwenty-three patients (median age, 9 years; 70% male) were included, with a median posttransplant time of 13 months. All received tacrolimus; most received mycophenolate (87%) and corticosteroids (39%). Post-SOT seroprotection was achieved in 48% of patients, and 82% showed HBV-specific CD4+ and CD8+ T-cell responses. Higher vaccine doses (3-4 doses) were associated with stronger immune responses. NK cell responses were observed in 56% (total NK cells) and 61% (NK T cells). NK responders showed higher expression of the activating receptor NKG2C. Baseline monocyte, dendritic cell and memory T-cell frequencies were positively correlated with post-SOT vaccination response.
conclusionsPediatric HTRs showed a generally good immune response to HBV revaccination, especially with higher vaccine doses. The immune profile at the time of vaccination appears to influence outcomes, supporting personalized vaccination approaches in immunosuppressed populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.